Results 91 to 100 of about 30,003 (287)

Treatment of psoriasis with biologic agents in Malta [PDF]

, 2016
Introduction: Biologic therapy has revolutionalised the treatment of moderate to severe psoriasis leading to improved clinical outcomes and quality of life scores.
Aquilina, Susan, Boffa, Michael J., Clark, Eileen, Mercieca, Liam, Scerri, Lawrence   +4 more
core  

Position Paper Português Sobre o Uso de Biossimilares na Psoríase [PDF]

, 2016
info:eu-repo/semantics ...
Ferreira, A., Ferreira, P., Filipe, P., Henriques, M., Leite, L., Magina, S., Marques-Pinto, G., Massa, A., Oliveira, H., Selores, M., Sousa-Basto, A., Tavares-Bello, R., Torres, T., Varela, P.   +13 more
core   +2 more sources

Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods These guidelines are an
Eytan Wine, Marina Aloi, Stephanie Van Biervliet, Jiri Bronsky, Javier Martín di Carpi, Marco Gasparetto, Laura Gianolio, Hannah Gordon, Iva Hojsak, Alexandra S. Hudson, Séamus Hussey, Johan van Limbergen, Erasmo Miele, Lorenzo Norsa, Ola Olén, Gianluca Pellino, Patrick van Rheenen, Lissy de Ridder, Richard K. Russell, Dror S. Shouval, Eunice Trindade, Dan Turner, David C. Wilson, Anat Yerushalmy Feler, Amit Assa   +24 more
wiley   +1 more source

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden [PDF]

, 2013
INTRODUCTION: A new treatment plan was implemented at Skåne University Hospital, on economic grounds, for children requiring recombinant human growth hormone (rhGH) treatment.
Carl-Erik Flodmark, Heike Woehling, Kajsa Järvholm, Katarina Lilja   +3 more
core   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America

Neurology and Therapy, 2019
The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient access to these therapies.
Judith Steinberg, Yara D. Fragoso, Juan Carlos Duran Quiroz, Juan Raul García, Caroline Guerra, Virginia Rodriguez, Claudia Carcamo Rodriguez, Ethel Ciampi, Edgar Correa-Diaz, Miguel Macías, Nelson Novarro, Darwin Vizcarra, Carlos Oehninger Gatti, Geraldine Orozco, Adriana Carrá   +14 more
doaj   +1 more source

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany

Pharmaceuticals, 2020
Drug budget and prescription control measures are implemented regionally in Germany, meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region.
Evelien Moorkens, Teresa Barcina Lacosta, Arnold G. Vulto, Martin Schulz, Gabriele Gradl, Salka Enners, Gisbert Selke, Isabelle Huys, Steven Simoens   +8 more
doaj   +1 more source

Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice? [PDF]

, 2019
Patent protection for pharmaceuticals in the United States is very robust and perhaps there is no greater example than epoetin alfa. Since the approval of epoetin alfa by the Food and Drug Administration (FDA) in 1989, the developer, Amgen (Thousand Oaks,
Wish, Jay B.
core   +1 more source

Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies

Drug Metabolism and Pharmacokinetics, 2019
The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory framework for biosimilar has also been established in the US, Japan, and other countries. As of 2018, biosimilars for infliximab, adalimumab, rituximab, trastuzumab, and bevacizumab have been approved.
Takashi Kuwabara, Akiko Ishii-Watabe
openaire   +3 more sources

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source